The British Business Bank is a government-owned development bank created to increase the supply and diversity of finance for smaller businesses in the UK.
The round was led by Sofina with participation from Better Society Capital and existing investors.
"Stream exemplifies how placing impact considerations at the heart of product development can drive sustainable commercial value. Its focus on tackling the 'poverty premium' not only works to improve financial resilience, but also solve critical challenges for employers. Stream's dedication to understanding and improving their products' impact on users enables greater positive outcomes and propels their strong commercial growth, and we look forward to the impact this funding will support."
The financing extension brings Nuclera's total Series C funding to $87m and will advance antibody engineering capabilities.
"Since our initial investment, Nuclera has made meaningful progress in expanding the capabilities, adoption, and global reach of the eProtein Discovery platform. The extension of the system into full-format antibody expression, purification, and binding validation represents a significant step forward, particularly as biologics discovery becomes increasingly driven by AI-enabled workflows that require scalable, high-quality datasets. Elevage is proud to continue supporting Nuclera as it evolves into a foundational platform for protein and antibody engineering, helping researchers accelerate discovery timelines and reduce friction across the drug development process."
The Kent biotechnology spinout raised the capital from backers including XGEN Venture and the British Business Bank to push its lead treatment into clinical evaluation.
"Refractory epilepsy is a devastating condition causing unpredictable and life-threatening seizures, and affecting millions of patients worldwide. Our novel gene therapy EPY201 delivered directly to the seizure focus has the potential to stop seizures with a single, minimally invasive administration. In doing so, it will change the way refractory epilepsy has been treated for decades. We are proud to have the support of such high calibre investors as we progress into clinical trials."
Haatch led the pre-seed round with backing from the East Midlands Combined Authority and the British Business Bank.
"Our platform enables people in the business to onboard AI Teammates where work happens, whilst real-time guardrails and audit logs protect and govern. Customers gain AI productivity at speed, with regulatory-compliant trust."
